NASDAQ:LIPO Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis $2.93 -0.15 (-4.87%) Closing price 03:57 PM EasternExtended Trading$2.56 -0.38 (-12.80%) As of 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lipella Pharmaceuticals Stock (NASDAQ:LIPO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get LIPO alerts:Sign Up Key Stats Today's Range$2.80▼$3.0550-Day Range$2.18▼$3.0852-Week Range$1.97▼$12.00Volume22,428 shsAverage Volume721,451 shsMarket Capitalization$7.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewLipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.Read More… Lipella Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreLIPO MarketRank™: Lipella Pharmaceuticals scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Lipella Pharmaceuticals. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Lipella Pharmaceuticals is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lipella Pharmaceuticals is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLipella Pharmaceuticals has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.03% of the float of Lipella Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLipella Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lipella Pharmaceuticals has recently increased by 671.68%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLipella Pharmaceuticals does not currently pay a dividend.Dividend GrowthLipella Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.03% of the float of Lipella Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLipella Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lipella Pharmaceuticals has recently increased by 671.68%, indicating that investor sentiment is decreasing significantly. News and Social Media2.1 / 5News Sentiment-0.24 News SentimentLipella Pharmaceuticals has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lipella Pharmaceuticals this week, compared to 1 article on an average week.Search Interest1 people have searched for LIPO on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Lipella Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lipella Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders32.11% of the stock of Lipella Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.31% of the stock of Lipella Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lipella Pharmaceuticals' insider trading history. Receive LIPO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lipella Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address LIPO Stock News HeadlinesLipella Pharmaceuticals to appeal Nasdaq noncompliance warningMay 20 at 9:37 AM | bizjournals.comLipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International MeetingMay 15, 2025 | globenewswire.comBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.May 21, 2025 | Crypto 101 Media (Ad)Lipella abstract on LP-10 for OLP accepted for presentation at AAOM, EAOMApril 25, 2025 | markets.businessinsider.comLipella Pharmaceuticals Inc.: Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025April 24, 2025 | finanznachrichten.deLipella Reports Additional Positive Data from Phase 2a Trial of LP-310 in Oral Lichen PlanusApril 24, 2025 | theglobeandmail.comLipella Pharmaceuticals announces results from second cohort of LP-310 trialApril 24, 2025 | markets.businessinsider.comLipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”April 23, 2025 | globenewswire.comSee More Headlines LIPO Stock Analysis - Frequently Asked Questions How have LIPO shares performed this year? Lipella Pharmaceuticals' stock was trading at $3.05 at the beginning of 2025. Since then, LIPO stock has decreased by 3.9% and is now trading at $2.93. View the best growth stocks for 2025 here. How were Lipella Pharmaceuticals' earnings last quarter? Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) announced its earnings results on Wednesday, May, 14th. The company reported ($0.64) earnings per share (EPS) for the quarter. The firm had revenue of $0.13 million for the quarter. Lipella Pharmaceuticals had a negative trailing twelve-month return on equity of 192.33% and a negative net margin of 882.82%. When did Lipella Pharmaceuticals' stock split? Shares of Lipella Pharmaceuticals reverse split on Friday, November 8th 2024. A 1-8 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Lipella Pharmaceuticals IPO? Lipella Pharmaceuticals (LIPO) raised $7 million in an initial public offering (IPO) on Tuesday, December 20th 2022. The company issued 1,217,391 shares at a price of $5.75 per share. How do I buy shares of Lipella Pharmaceuticals? Shares of LIPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lipella Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lipella Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), MSP Recovery (LIFW), MSP Recovery (LIFW), NVIDIA (NVDA), Processa Pharmaceuticals (PCSA), Energy Transfer (ET) and Labor Smart (LTNC). Company Calendar Last Earnings5/14/2025Today5/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LIPO CIK1347242 Weblipella.com Phone412-901-0315FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,620,000.00 Net Margins-882.82% Pretax Margin-882.61% Return on Equity-192.33% Return on Assets-154.24% Debt Debt-to-Equity RatioN/A Current Ratio2.97 Quick Ratio2.97 Sales & Book Value Annual Sales$536,357.00 Price / Sales13.92 Cash FlowN/A Price / Cash FlowN/A Book Value$4.33 per share Price / Book0.68Miscellaneous Outstanding Shares2,549,000Free Float821,000Market Cap$7.47 million OptionableNot Optionable Beta0.26 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:LIPO) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipella Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.